Clinical Trials at UPMC Hillman Cancer Center
As of August 2026, 145 paid clinical trials are recruiting at UPMC Hillman Cancer Center, located at UPMC Hillman Cancer Center: Research Pavilion, 5115 Centre Ave # 2, Pittsburgh, PA 15232 in Pittsburgh, Pennsylvania. Active studies at this site cover conditions such as Breast Cancer, Melanoma and Stroke. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
145 clinical trials at UPMC Hillman Cancer Center
·Clear filters·A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Neoadjuvant Darovasertib in Primary Uveal Melanoma
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
A Phase 1 Study of the Safety and Tolerability of CTX-10726
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Common conditions studied in Pittsburgh
- Breast Cancer (25 active studies)
- Cancer (19 active studies)
- Melanoma (18 active studies)
- Stroke (17 active studies)
- Endometrial Cancer (16 active studies)
- Ovarian Cancer (16 active studies)
Leading research sponsors in Pittsburgh
- University of Pittsburgh
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Oncology Group
- VA Office of Research and Development
Frequently asked questions
How many paid clinical trials are currently recruiting in Pittsburgh?
There are approximately 1,247 recruiting clinical trials in Pittsburgh, Pennsylvania listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Pittsburgh pay participants?
Most recruiting trials in Pittsburgh compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Pittsburgh?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Pittsburgh?
The most common conditions under active study in Pittsburgh include Breast Cancer (25), Cancer (19), Melanoma (18), Stroke (17), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Pittsburgh?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Pittsburgh on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Pittsburgh?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Pittsburgh?
Recruiting research sites in Pittsburgh include University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Pittsburgh right now?
The largest active categories in Pittsburgh are Cancer & tumors (402), Neurology & pain (84), Cardiovascular (71). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of UPMC Hillman Cancer Center?
UPMC Hillman Cancer Center is located at UPMC Hillman Cancer Center: Research Pavilion, 5115 Centre Ave # 2, Pittsburgh, PA 15232. Use the Google Maps link in the intro above to get directions.